---
title: "Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253428236.md"
description: "According to the Zhitong Finance APP, Kanion Pharmaceutical announced that the company has received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration for the Jianpi Shugan Guben Granules. The relevant drug is Jianpi Shugan Guben Granules, indicated for diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency"
datetime: "2025-08-18T09:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253428236.md)
  - [en](https://longbridge.com/en/news/253428236.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253428236.md)
---

# Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved

According to the Zhitong Finance APP, Kanion Pharmaceutical (600557.SH) announced that the company has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration for the product Jianpi Shugan Guben Granules. The indication for this drug is diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency

### Related Stocks

- [600557.CN](https://longbridge.com/en/quote/600557.CN.md)

## Related News & Research

- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [CMOC Group (CMCLF): New Buy Recommendation for This Basic Materials Giant](https://longbridge.com/en/news/286625840.md)
- [NYC Health and Hospitals says hackers stole medical data and fingerprints during breach affecting at least 1.8 million people](https://longbridge.com/en/news/286799449.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Managers' transactions announcement according to article 19 MAR](https://longbridge.com/en/news/286901864.md)